Regulatory

Latest News

FDA Expands Approval of Sarepta Therapeutics’ Elevidys for the Treatment of Duchenne Muscular Dystrophy
FDA Expands Approval of Sarepta Therapeutics’ Elevidys for the Treatment of Duchenne Muscular Dystrophy

June 21st 2024

Expansion of Elevidys includes patients over the age of four years with Duchenne muscular dystrophy regardless of their ambulatory status.

Image Credit: Adobe Stock Images/Siam
FDA Approves Botanix Pharmaceuticals’ Sofdra for the Treatment of Primary Axillary Hyperhidrosis

June 20th 2024

FDA Approves AbbVie’s Skyrizi for the Treatment of Adults with Moderate to Severely Active Ulcerative Colitis
FDA Approves AbbVie’s Skyrizi for the Treatment of Adults with Moderate to Severely Active Ulcerative Colitis

June 19th 2024

FDA Approves Merck’s Keytruda in Combination with Carboplatin and Paclitaxel to Treat Advanced or Recurrent Endometrial Carcinoma
FDA Approves Merck’s Keytruda in Combination with Carboplatin and Paclitaxel to Treat Advanced or Recurrent Endometrial Carcinoma

June 18th 2024

FDA Approves Merck’s Capvaxive to Prevent Invasive Pneumococcal Disease, Pneumococcal Pneumonia in Adults Over 18 Years of Age
FDA Approves Merck’s Capvaxive to Prevent Invasive Pneumococcal Disease, Pneumococcal Pneumonia in Adults Over 18 Years of Age

June 18th 2024

More News